Literature DB >> 12586213

Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats.

Yuko Muto1, Kokichi Suzuki, Eriko Sato, Hidemi Ishii.   

Abstract

Procarboxypeptidase B (also known as thrombin-activatable fibrinolysis inhibitor) is a recently described plasma zymogen known to be activated by thrombin in plasma. Carboxy-terminal lysine residues from partially degraded fibrin are important for the binding and activation of plasminogen, and carboxypeptidase B, an active form of procarboxypeptidase B, has been shown to inhibit fibrinolysis by eliminating these residues. The present paper investigates the effects of carboxypeptidase B inhibitors, DL-mercaptomethyl-3-guanidinoethylthiopropanoic acid (MGPA) and potato-derived carboxypeptidase inhibitor (CPI), on tissue factor (TF)-induced microthrombosis in rats. Intravenous injection of MGPA (3 mg/kg and higher) or CPI (0.3 mg/kg and higher) after microthrombi formation dramatically attenuated TF-induced glomerular fibrin deposition with an increase in plasma levels of D-dimer. These results indicate that carboxypeptidase B inhibitors can enhance endogenous fibrinolysis and reduce thrombi in the TF-induced microthrombosis model after systemic administration even after thrombi formation. Copyright 2003 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586213     DOI: 10.1016/s0014-2999(03)01297-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.

Authors:  Xinkang Wang; Patricia L Smith; Mei-Yin Hsu; Joseph A Tamasi; Eileen Bird; William A Schumacher
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

Review 2.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

3.  In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases.

Authors:  Mélissa Jean; Lajos Gera; Xavier Charest-Morin; François Marceau; Hélène Bachelard
Journal:  Front Pharmacol       Date:  2016-01-12       Impact factor: 5.810

4.  D-Arg0-Bradykinin-Arg-Arg, a Latent Vasoactive Bradykinin B2 Receptor Agonist Metabolically Activated by Carboxypeptidases.

Authors:  Hélène Bachelard; Xavier Charest-Morin; François Marceau
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.